JNJ

238.83

-0.49%↓

UNH

276.32

-0.03%↓

ABT

110.54

-0.25%↓

ISRG

492.55

+1.09%↑

DHR

217.43

+0.44%↑

JNJ

238.83

-0.49%↓

UNH

276.32

-0.03%↓

ABT

110.54

-0.25%↓

ISRG

492.55

+1.09%↑

DHR

217.43

+0.44%↑

JNJ

238.83

-0.49%↓

UNH

276.32

-0.03%↓

ABT

110.54

-0.25%↓

ISRG

492.55

+1.09%↑

DHR

217.43

+0.44%↑

JNJ

238.83

-0.49%↓

UNH

276.32

-0.03%↓

ABT

110.54

-0.25%↓

ISRG

492.55

+1.09%↑

DHR

217.43

+0.44%↑

JNJ

238.83

-0.49%↓

UNH

276.32

-0.03%↓

ABT

110.54

-0.25%↓

ISRG

492.55

+1.09%↑

DHR

217.43

+0.44%↑

Search

Thermo Fisher Scientific Inc

Deschisă

SectorSănătate

546.88 0.89

Rezumat

Modificarea prețului

24h

Curent

Minim

535

Maxim

548.43

Indicatori cheie

By Trading Economics

Venit

349M

2B

Vânzări

1.1B

12B

P/E

Medie Sector

32.794

84.243

Randament dividend

0.3

Marjă de profit

16.128

Angajați

125,000

EBITDA

191M

3B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+24.85% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.30%

2.28%

Următoarele câștiguri

22 apr. 2026

Data viitoare de dividende

14 apr. 2026

Următoarea dată ex-dividende

13 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-17B

219B

Deschiderea anterioară

545.99

Închiderea anterioară

546.88

Sentimentul știrilor

By Acuity

53%

47%

274 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Thermo Fisher Scientific Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 ian. 2026, 11:34 UTC

Câștiguri

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

29 oct. 2025, 10:51 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific Agrees to Buy Clario Holdings for $8.88 billion

23 oct. 2025, 20:49 UTC

Câștiguri

Correction to Thermo Fisher Article on Oct. 22

22 oct. 2025, 10:28 UTC

Câștiguri

Thermo Fisher 3Q Revenue Rises, Boosted by Life Sciences Business

23 iul. 2025, 10:33 UTC

Câștiguri

Thermo Fisher Scientific 2Q Profit, Revenue Rise

29 ian. 2026, 11:01 UTC

Câștiguri

Thermo Fisher 4Q Organic Revenue Rose 3% >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher: Entering 2026 From Position of Strength >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Net $1.96B >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Rev $12.22B >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q EPS $5.21 >TMO

29 ian. 2026, 11:00 UTC

Câștiguri

Thermo Fisher 4Q Adj EPS $6.57 >TMO

29 oct. 2025, 10:06 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher: Clario Provides Endpoint Data Solutions for Clinical Trials >TMO

29 oct. 2025, 10:05 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher: Claro Deal Includes Potential Additional Earnout, Other Payments >TMO

29 oct. 2025, 10:05 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher to Buy Clario From Group Led by Astorg and Nordic Cap, Novo Holding, Cinven >TMO

29 oct. 2025, 10:04 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific to Pay $8.875 Billion at Closing for Clario Holdings >TMO

29 oct. 2025, 10:00 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific to Acquire Clario Holdings >TMO

22 oct. 2025, 10:01 UTC

Câștiguri

Thermo Fisher 3Q Organic Revenue Rose 3% >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher: In Great Position to Deliver on 2025 Objectives >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Adj EPS $5.79 >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Rev $11.12B >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 3Q Net $1.62B >TMO

22 oct. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 3Q EPS $4.27 >TMO

2 sept. 2025, 12:15 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Scientific Completes Acquisition Of Sanofi's Ridgefield, New Jersey Site >TMO

2 sept. 2025, 12:08 UTC

Achiziții, Fuziuni, Preluări

Solventum Had Seen 2025 Adjusted EPS $5.80-$5.95 >SOLV

2 sept. 2025, 12:08 UTC

Achiziții, Fuziuni, Preluări

Solventum Raises 2025 View To Adj EPS $5.88-Adj EPS $6.03 >SOLV

2 sept. 2025, 12:04 UTC

Achiziții, Fuziuni, Preluări

Solventum to Use Net Proceeds Primarily to Pay Down Debt >SOLV

2 sept. 2025, 12:03 UTC

Achiziții, Fuziuni, Preluări

Solventum Closes Sale of Unit to Thermo Fisher for $4 Billion in Cash >SOLV

2 sept. 2025, 12:03 UTC

Achiziții, Fuziuni, Preluări

Thermo Fisher Completes Acquisition of Purification & Filtration Business of Solventum for About $4B in Cash >TMO

2 sept. 2025, 12:00 UTC

Achiziții, Fuziuni, Preluări

Solventum Completes Sale of Purification & Filtration Business to Thermo Fisher Scientific >SOLV TMO

23 iul. 2025, 10:00 UTC

Câștiguri

Thermo Fisher 2Q Organic Revenue Rose 2% >TMO

Comparație

Modificare preț

Thermo Fisher Scientific Inc Așteptări

Obiectiv de preț

By TipRanks

24.85% sus

Prognoză pe 12 luni

Medie 677.73 USD  24.85%

Maxim 750 USD

Minim 615 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruThermo Fisher Scientific Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

15

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

406.5 / 417.79Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Strong Bearish Evidence

Sentiment

By Acuity

274 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. It has a collaboration agreement with Mainz Biomed N.V. for the development of colorectal cancer screening product. Thermo Fisher Scientific Inc. was founded in 1956 and is headquar
help-icon Live chat